Cheryl L. Willman, M.D., director of the UNM Cancer Research & Treatment Center (CRTC), and Robert Hromas, M.D., deputy director for clinical services and clinical investigations at the UNM CRTC, have been named to the National Institutes of Health Hematopoiesis Study Section.

           

Willman will serve as chairwoman of the study section. Part of the NIH's Center for Scientific Review, study sections are panels of experts established according to scientific disciplines or current research areas for the primary purpose of evaluating the scientific and technical merit of grant applications.  Hematopoiesis deals with the formation of blood or blood cells.

 

Willman is an internationally recognized cancer researcher and leads a consortium of investigators at UNM, Sandia National Laboratories and the New Mexico biotechnology community who are applying the advances from the Human Genome Project to cancer research.  Hromas is a nationally recognized expert in blood cell diseases and cancers (leukemia, lymphoma and myeloma.)

 

"I know Drs. Willman and Hromas will be real assets to this group," said Paul B. Roth, M.D., dean of the UNM School of Medicine and associate vice president for academic affairs at the UNM Health Sciences Center.

 

Founded in 1972, the UNM Cancer Research & Treatment Center is the only academic health care facility that is dedicated to both cancer research and patient care.

 


Contact: Lynn Melton, 272-3322